Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Race Oncology Ltd. ( (AU:RAC) ) is now available.
Racura Oncology Ltd announced the issuance of 1,139,027 new shares at $2.83 each as part of a capital raising effort. This move allows immediate trading of the shares, potentially enhancing liquidity and supporting the company’s ongoing clinical programs and strategic initiatives in the oncology sector.
More about Race Oncology Ltd.
Racura Oncology Ltd is a Phase 3 clinical biopharmaceutical company focused on cancer care. Its lead product, RCDS1, is an anticancer agent targeting cancer growth regulators. Racura is advancing RCDS1 in various clinical programs and exploring partnerships to expand access globally.
Average Trading Volume: 548,491
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$478.3M
Find detailed analytics on RAC stock on TipRanks’ Stock Analysis page.